GlassScriptPhysician profile
Kevin O Clarke
NPI 1598789265
$5,865.69
in general payments reported to CMS, 2019-2025
20 companies · $889 in 2025
The $889 reported for 2025 was more than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $50.94 · 2021: $1,062 · 2022: $2,112 · 2023: $331 · 2024: $1,295 · 2025: $889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,855 · Travel and Lodging: $660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,855.25 |
| Travel and Lodging | $660.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,483.19 | 2021-2025 | |
| Axogen | $974.77 | 2024 | Axoguard Nerve Connector, Avance Nerve Graft, Axoguard Ha+ Nerve Protector |
| Convatec INC. | $291.04 | 2022-2025 | |
| Smith+Nephew, INC. | $255.24 | 2019-2025 | Collagenase Santyl, Regranex |
| Dilon Technologies, INC. | $149.31 | 2025 | Hemoblast Bellows |
| Baxter Healthcare | $116.51 | 2023 | Floseal |
| Ethicon US, LLC | $97.11 | 2019-2024 | Harmonic |
| Merck Sharp & Dohme LLC | $93.66 | 2023-2024 | Keytruda |
| E.R. Squibb & Sons, L.L.C. | $88.33 | 2024 | |
| Kci USA, INC. | $82.80 | 2020-2023 | Prevena, V.A.C. Veraflo, V.A.C.Ulta |
| Solventum Corporation | $52.20 | 2024-2025 | Prevena, V.A.C.Ulta, V.A.C.Instill |
| Pacira Pharmaceuticals Incorporated | $31.35 | 2022 | |
| Next Science LLC | $27.66 | 2023 | Blastx, Surgx, Xperience |
| Avanos Medical | $26.13 | 2019 | |
| Lilly USA, LLC | $19.36 | 2025 | Verzenio, Jaypirca |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $17.52 | 2025 | Enhertu |
| Celgene Corporation | $16.98 | 2023 | Zeposia |
| W. L. Gore & Associates, INC. | $14.88 | 2022 | |
| Davol INC. | $14.16 | 2021 | |
| Intra-Sana Laboratories | $13.49 | 2023 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Clarke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.